A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

著者: S. Loibl, Michael Untch, Nicole Burchardi, Jens Huober, Bruno V. Sinn, Jens‐Uwe Blohmer, Eva‐Maria Grischke, Jenny Furlanetto, Hans Tesch, Claus Hanusch, Knut Engels, Mahdi Rezai, Christian Jackisch, Wolfgang Schmitt, Gϋnter von Minckwitz, Jörg Thomalla, Sherko Kümmel, Beate Rautenberg, Peter A. Fasching, Karsten E. Weber, Kerstin Rhiem, Carsten Denkert, Andreas Schneeweiß - Annals of Oncology 2019 被引用: 694